Wund(er)heilung mit Amnion – DGFG erhält deutschen Wundpreis 2021
Ausschreibung DGNI-Pflege- und Therapiepreis 2022
Ausschreibung: Otsuka Team Award Psychiatry+ 2021
BGW-Gesundheitspreis 2022: Gute Praxis aus der Altenpflege gesucht!
Aktionsbündnis Patientensicherheit vergibt Deutschen Preis für Patientensicherheit 2021 an herausragende…
8.-10. September 2021: Weimar Sepsis Update 2021 – Beyond the…
13.09. – 18.09.2021: Viszeralmedizin 2021
24.06. – 26.06.2021: 27. Jahrestagung der Deutschen Gesellschaft für Radioonkologie
17.06. – 19.06.2021: 47. Jahrestagung der Gesellschaft für Neonatologie und…
16. bis 18. Juni 2021: Deutscher Kongress für Psychosomatische Medizin…
European Medicines Agency finalises first set of guidelines on good pharmacovigilance practices
London, UK (June 25, 2012) – The European Medicines Agency has published the first set of finalised modules of the guideline on good pharmacovigilance practices (GVP) today.
The finalisation of these seven modules is a key deliverable of the 2010 pharmacovigilance legislation, which will apply from Monday 2 July 2012. Each of the modules covers one major process in the safety monitoring of medicines. These are:
Module I: Pharmacovigilance systems and their quality systems;
Module II: Pharmacovigilance systems master files;
Module V: Risk management systems;
Module VI: Management and reporting of adverse reactions to medicinal products;
Module VII: Periodic safety update reports;
Module VIII: Post-authorisation safety studies;
Module IX: Signal management.
GVP is a set of measures drawn up to facilitate the performance of pharmacovigilance in the European Union (EU). They apply to marketing-authorisation holders, the Agency and medicines regulatory authorities in EU Member States and aim to improve safety for patients by strengthening the monitoring of the safety of medicines across the EU. They cover medicines authorised centrally via the Agency as well as medicines authorised at national level.
Each module was developed by a team consisting of experts from the Agency and from EU Member States, and was released for public consultation between February and April 2012. The final versions of the modules have been updated, taking the comments received during the public consultation into account. The comments received have also been published today.
On Wednesday 27 June 2012, the Agency will be publishing two further GVP modules for public consultation. These will be:
Module II: Pharmacovigilance inspections;
Module X: Additional monitoring.
The remaining seven draft modules making up the entire GVP package are under development and will be released for consultation later in the year.
The GVP modules are aligned with the European Commission’s implementing regulation
The finalised GVP modules on post-authorisation safety studies and risk management plans refer to the guide on methodological standards in pharmacoepidemiology
Today also sees the publication of an updated version of the European Medicines Agency and Member States joint implementation checklist (http://www.ema.europa.eu/ema/pages/includes/document/open_document.jsp?webContentId=WC500105351), which provides an overview of the prioritisation of tasks linked to the implementation of the legislation.
European Medicines Agency, 25.06.2012 (tB).